Compare GXO Logistics Inc (GXO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GXO Logistics Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? GXO Logistics Inc trades at $52.8 (market cap $6.07B), while Vertex Pharmaceuticals Incorporated trades at $480 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 20.1× GXO Logistics Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, GXO Logistics Inc nearer its low. Which is the better fit depends on your goals.
| GXO | VRTX | |
|---|---|---|
Market Cap | $6.07B | $121.95B |
Sector | Industrials | Health |
52-Week High | $65.59 | $529.59 |
52-Week Low | $45.52 | $366.54 |
Enterprise Value | $11.24B | $116.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GXO Logistics trades at $52.80, down 2.31% today, with strong analyst support showing 16 buy ratings and an average price target of $66.60. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $0.50 surpassing the $0.37 estimate. Technical indicators show a bullish trend with moving averages supporting upward momentum, while fundamentals reveal revenue growth to $13.18 billion in 2025 with improving profitability margins expected in 2026.
GXO presents a compelling investment case with 36% upside to consensus targets, supported by strong earnings momentum and expanding partnerships. Key risks include competitive pressures in logistics and Amazon's market entry, while the company's focus on high-growth verticals and record sales pipeline provides growth catalysts. The stock's current valuation at 48.26 P/E requires continued execution to justify premium multiples.
Vertex Pharmaceuticals (VRTX) trades at $480.51, down 1.06% on the day, with a bullish technical signal driven by moving averages. The stock shows strong profitability with a 35.51% net income margin and robust cash flow, though it faces a recent earnings miss. A major $10 billion acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology portfolio, adding potential for significant future revenue growth.
The outlook remains positive with an 85.71% analyst buy rating and a $538 consensus price target, implying 12% upside. Key risks include integration challenges from the acquisition and reliance on cystic fibrosis treatments. Earnings growth and successful pipeline execution are critical catalysts for sustained appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About GXO Logistics Inc
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
